Condition
LGMD2I
Total Trials
6
Recruiting
2
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting2
Completed2
Unknown1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05230459Phase 1Recruiting
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
NCT03842878CompletedPrimary
Natural History Study of Patients With Limb-Girdle Muscular Dystrophy 2I
NCT05989620Recruiting
Long-Term Development of Muscular Dystrophy Outcome Assessments
NCT04800874Phase 2Active Not RecruitingPrimary
Study of BBP-418 in Patients With LGMD2I
NCT04001595UnknownPrimary
Global FKRP Registry
NCT02841267Phase 1CompletedPrimary
A Trial of PF-06252616 in Ambulatory Participants With LGMD2I
Showing all 6 trials